首页|单核细胞/高密度脂蛋白胆固醇比值与冠心病相关性的研究进展

单核细胞/高密度脂蛋白胆固醇比值与冠心病相关性的研究进展

扫码查看
近年来,全球冠心病的发病率及病死率处于逐年升高态势,已严重危害人类健康。因此,早期筛查冠心病的高危人群并对其及时采取防治措施,对于降低该病的病死率、改善远期预后等具有重大的临床意义。既往已知,冠心病发生的病理基础是动脉血管粥样硬化形成,而产生动脉粥样硬化的基本病理机制为机体炎症反应。单核细胞/高密度脂蛋白胆固醇比值(MHR)作为一种新的炎症性生物标志物,不仅整合了机体的炎症状态及抗炎能力,同时还兼具临床易获得、经济等优势,国内外现已有大量研究证实其对于预测冠心病的发生发展、冠状动脉病变程度乃至冠心病的近远期预后均具有很大潜力。本文就MHR与冠心病相关性的研究进展做一综述。
Research progress on the correlation between monocyte/high-density lipoprotein cholesterol ratio and coronary heart disease
In recent years,the global incidence and mortality of coronary heart disease have been increasing year by year,which has seriously endangered human health.Therefore,early screening of high-risk populations for coronary heart disease and timely implementation of prevention and treatment measures have significant clinical significance for reducing the mortality of the disease and improving long-term prognosis.It is known that the pathological basis of coronary heart disease is the formation of arterial atherosclerosis,and the basic pathological mechanism of atherosclerosis is the body's inflammatory reaction.Monocyte/high-density lipoprotein cholesterol ratio(MHR),as a new inflammatory biomarker,not only integrates the inflammatory state and anti-inflammatory ability of the body,but also has advantages such as clinical accessibility and economy.Currently,a large number of studies at home and abroad have confirmed that it has great potential for predicting the occurrence and development of coronary heart disease,the degree of coronary artery disease,and even the short-term and long-term prognosis of coronary heart disease.This article provides a review of the research progress on the correlation between MHR and coronary heart disease.

Coronary heart diseaseMonocytesHigh-density lipoprotein cholesterolMonocytes/high-density lipoprotein cholesterolInflammation

叶雪瑞、万秋华、杨鑫伟、刘有娟、李建美

展开 >

云南省阜外心血管病医院心内科,云南昆明 650000

冠心病 单核细胞 高密度脂蛋白胆固醇 单核细胞/高密度脂蛋白胆固醇 炎症

云南省教育厅科学研究基金项目云南省阜外心血管病医院院级科研基金项目

2021J0293202002AA310100-11

2024

中国医药科学
海峡两岸医药卫生交流协会 二十一世纪联合创新(北京)医药科学研究院

中国医药科学

影响因子:1.083
ISSN:2095-0616
年,卷(期):2024.14(8)
  • 33